Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asenapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 1.00 |
| ▸ | HTR2C | P28335 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | HTR3A | P46098 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asenapine SCHEMBL30544842 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL30413463 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL2221502 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL3805507 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL4060905 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL30876933 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL11537117 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL114123 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL8008417 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL29365680 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485099-B2 | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-12-02 | — | — | US | claimed |
| US-12329862-B2 | Transdermal therapeutic system containing asenapine | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-06-17 | — | — | US | claimed |
| US-12138353-B2 | Transdermal therapeutic system containing asenapine | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-11-12 | — | — | US | claimed |
| CN-114302716-B | Method for inhibiting the formation of asenapine-N-oxide | 久光制药株式会社 | 2024-09-17 | — | — | CN | claimed |
| US-11648213-B2 | Transdermal therapeutic system containing asenapine | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2023-05-16 | — | — | US | claimed |
| US-20220323370-A1 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND POLYSILOXANE OR POLYISOBUTYLENE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-10-13 | — | — | US | claimed |
| US-11337932-B2 | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-05-24 | — | — | US | claimed |
| US-12485099-B2 | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-12-02 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-12343329-B2 | Method for suppressing production of asenapine-N-oxide | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2025-07-01 | — | — | US | disclosed |
| US-12329862-B2 | Transdermal therapeutic system containing asenapine | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-06-17 | — | — | US | disclosed |
| CN-113226308-B | Adhesive patch containing asenapine | 久光制药株式会社 | 2024-12-10 | — | — | CN | disclosed |
| US-12138353-B2 | Transdermal therapeutic system containing asenapine | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-11-12 | — | — | US | disclosed |
| US-11590106-B2 | Asenapine-containing adhesive patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2023-02-28 | — | — | US | disclosed |
| US-11535628-B2 | Method for preparation of Asenapine | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-11535628-B2 | Method for preparation of Asenapine | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-11490856-B2 | Method and a system for analyzing neuropharmacology of a drug | CITY UNIVERSITY OF HONG KONG (HK) | 2022-11-08 | — | — | US | disclosed |
| US-20220323370-A1 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND POLYSILOXANE OR POLYISOBUTYLENE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-10-13 | — | — | US | disclosed |
| US-11337932-B2 | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-05-24 | — | — | US | disclosed |
| CN-114302716-A | Method for inhibiting the formation of asenapine-N-oxide | 久光制药株式会社 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323370-A1 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND POLYSILOXANE OR POLYISOBUTYLENE | TES, SLC6A2, PASK | DRD2 464/4885HTR2A 170/4885HTR2C 367/4885 |
| US-11535628-B2 | Method for preparation of Asenapine | CYP3A5, QDPR, SPR | DRD2 39/4885HTR2A 495/4885HTR2C 516/4885 |
| US-11337932-B2 | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene | TES, SLC6A2, PASK | DRD2 464/4885HTR2A 170/4885HTR2C 367/4885 |
| US-12485099-B2 | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene | TES, SLC6A2, PASK | DRD2 464/4885HTR2A 170/4885HTR2C 367/4885 |
| US-12343329-B2 | Method for suppressing production of asenapine-N-oxide | TPMT, CBS, TST | DRD2 846/4885HTR2A 493/4885HTR2C 705/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | DRD2 4342/4885HTR2A 1457/4885HTR2C 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.